<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00235820</url>
  </required_header>
  <id_info>
    <org_study_id>M04-716</org_study_id>
    <nct_id>NCT00235820</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis</brief_title>
  <acronym>CHAMPION</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate and
      Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects achieving clinical response at Week 16 relative to the Baseline (Week 0) PASI score.</measure>
    <time_frame>Week 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety parameters</measure>
    <time_frame>Every Study Visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment</measure>
    <time_frame>Baseline - Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PASI 50/90/100</measure>
    <time_frame>Baseline - Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLQI</measure>
    <time_frame>Baseline - Week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">271</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <description>40 mg every other week following an 80 mg dose</description>
    <arm_group_label>A</arm_group_label>
    <other_name>ABT-D2E7</other_name>
    <other_name>Humira</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX</intervention_name>
    <description>MTX 7.5 to 25 mg once weekly</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo adalimumab, placebo MTX</intervention_name>
    <description>placebo injections once every other week after 2 injections at Baseline (adalimumab) placebo capsules once weekly (MTX)</description>
    <arm_group_label>C</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject was age 18 or older and in good health (Investigator discretion) with a recent
             stable medical history who has had a diagnosis of psoriasis for at least 12 months and
             stable moderate to severe chronic plaque psoriasis

          -  Subject is a candidate for systemic therapy or phototherapy and has active psoriasis
             despite treatment with topical agents.

          -  Subject was able and willing to self-administer sc injections or had available
             qualified person(s) to administer sc injections.

          -  Male subjects must hve been vasectomized or practicing birth control.

        Exclusion Criteria:

          -  Previous systemic anti-TNF therapy.

          -  Prior use of MTX.

          -  Known hypersensitivity to the constituents of adalimumab.

          -  Systemic therapy for psoriasis for at least 4 weeks prior to Baseline; except for
             biologic therapies, which must be discontinued at least 12 weeks prior to enrollment.

          -  Topical psoriasis therapy for at least 2 weeks prior to Baseline, except for
             non-corticosteroid shampoos, bland (no alpha or beta hydroxy) emollients and low
             potency topical corticosteroids on the palms, soles, face, inframammary area, and
             groin only.

          -  Use of tanning beds, excessive sun exposure, or phototherapy (UVB, UVA), for at least
             2 weeks prior to Baseline.

          -  Use of PUVA for at least 4 weeks prior to Baseline.

          -  Use of oral or injectable corticosteroids during the study.

          -  Subject considered by the investigator, for any reason, to be an unsuitable candidate
             for the study.

          -  Female subject who is pregnant or breast feeding or considering becoming pregnant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Medical Information</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Global Medical Information-Abbott</name>
      <address>
        <city>Abbott Park</city>
        <state>Illinois</state>
        <zip>60064</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2005</study_first_submitted>
  <study_first_submitted_qc>October 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2005</study_first_posted>
  <last_update_submitted>July 15, 2008</last_update_submitted>
  <last_update_submitted_qc>July 15, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2008</last_update_posted>
  <responsible_party>
    <name_title>Beverly Papierello/Director, Clinical Program Management</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>adalimumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

